ArticleOpen forum infectious diseases2020
Performance of the T2Candida Panel for the Diagnosis of Intra-abdominal Candidiasis.
Article in Open forum infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Invasive fungal disease in patients with end-stage liver disease.Infectious diseases & immunity · 2026Review
- Diagnostic Biomarkers for Invasive Candidiasis: A Clinician-Oriented Review.Journal of fungi (Basel, Switzerland) · 2026Review
- Diagnostic Approaches to Invasive Candidiasis: Challenges and New Perspectives.Mycopathologia · 2025Review
- Review on the management of intra-abdominal candidiasis.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2025Review
- The Molecular Diagnosis of Invasive Fungal Diseases with a Focus on PCR.Diagnostics (Basel, Switzerland) · 2025Review
- Evaluating antimicrobial stewardship strategies in candidemia: a novel desirability of outcome ranking (DOOR) analysis comparing blood culture versus T2Candida diagnostic approaches.Journal of clinical microbiology · 2025Observational
- Review
- Invasive Fungal Infections in Immunocompromised Conditions: Emphasis on COVID-19.Current microbiology · 2024Review
- Performance of a Real-Time PCR Assay for the Detection of FiveJournal of fungi (Basel, Switzerland) · 2023Article
- T2Candida assay: diagnostic performance and impact on antifungal prescribing.JAC-antimicrobial resistance · 2023Article
- Quantitatively detectingFrontiers in microbiology · 2023Article
- Effective Rapid Diagnosis of Bacterial and Fungal Bloodstream Infections by T2 Magnetic Resonance Technology in the Pediatric Population.Journal of clinical microbiology · 2022Article
- The Changing Landscape of Invasive Fungal Infections in ICUs: A Need for Risk Stratification to Better Target Antifungal Drugs and the Threat of Resistance.Journal of fungi (Basel, Switzerland) · 2022Review
- Noninvasive Testing and Surrogate Markers in Invasive Fungal Diseases.Open forum infectious diseases · 2022Article
- T2Candida Assay in the Diagnosis of Intraabdominal Candidiasis: A Prospective Multicenter Study.Journal of fungi (Basel, Switzerland) · 2022Article
- Intensive Care Antifungal Stewardship Programme Based on T2Candida PCR andJournal of fungi (Basel, Switzerland) · 2021Article
- The rise in cases of mucormycosis, candidiasis and aspergillosis amidst COVID19.Fungal biology reviews · 2021Review
- Update on Non-Culture-Based Diagnostics for Invasive Fungal Disease.Mycopathologia · 2021Article
- T2Candida for the Diagnosis and Management of InvasiveJournal of fungi (Basel, Switzerland) · 2021Review
- Performance of Repeated Measures of (1-3)-β-D-Glucan, Mannan Antigen, and Antimannan Antibodies for the Diagnosis of Invasive Candidiasis in ICU Patients: A Preplanned Ancillary Analysis of the EMPIRICUS Randomized Clinical Trial.Open forum infectious diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Performance of T2Candida for detecting intra-abdominal candidiasis (IAC) was assessed in 48 high-risk patients. T2Candida sensitivity/specificity and positive/negative predictive values were 33%/93% and 71%/74%, respectively. IAC was present in 100% of cases with concordant positive T2Candida/1,3-beta-d-glucan and absent in 90% of concordant negative results. Combination T2Candida/1,3-beta-d-glucan may help guide treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.